P ulmonary arterial hypertension (PAH) is a progressive, devastating disease of the pulmonary vasculature that results in small-vessel occlusion and loss, increasing pulmonary vascular resistance and ultimately death resulting from right ventricular failure.
We and others have shown that an abnormal sex hormone milieu contributes to PAH risk and that modifying sex hormone exposures is a promising target. [8] [9] [10] [11] [12] [13] [14] [15] Estrogen production and metabolism is a complex process that changes over time and may occur in the sex-specific organs and peripherally 16 ; for example, aromatase, the rate-limiting enzyme in the conversion of androgens to parent compound estrogens, is expressed in ovarian and extragonadal tissues, including the lung. 8, 17 It was recently shown that variations in genes that contribute to estrogen signaling associate with PAH. 12, 13 Intriguingly, pulmonary artery smooth muscle cells (PASMCs) from female patients with PAH express more aromatase compared with male patients, and aromatase inhibitor (anastrozole) treatment attenuates pulmonary hypertension (PH) in female rodent PH models. 8 Although parent compound estrogens appear important to PAH, so too may be certain estrogen metabolites. BMPR2-associated HPAH in female patients associated with reduced expression of the estrogen metabolism gene CYP1B1, 18 which may skew metabolism of parent estrogens into the estrogen metabolite 16α-hydroxyestrone (16αOHE). We demonstrated that preferential metabolism to 16αOHE associated with disease penetrance in HPAH. 12 In addition, long-term 16αOHE exposure significantly increased PH penetrance and severity in murine models of Bmpr2-associated PH. [19] [20] [21] [22] The deleterious effects of 16αOHE appear to involve both cellular processes and systemic abnormalities, including suppression of cellular BMP signaling and alterations in energy metabolism, as well as induction of pulmonary vascular injury and systemic insulin resistance. [22] [23] [24] Thus, 16αOHE may promote cell-level alterations such as mitochondrial-metabolic abnormalities, 25 which ultimately promote systemic metabolic abnormalities in PAH, including insulin resistance and hyperglycemia. [26] [27] [28] [29] [30] The pathogenesis of PAH is likely a complex process involving the interplay of multiple factors, including not only the circulating milieu but also environmental, genetic, and epigenetic factors that influence gene and protein expression. For example, there is emerging interest in the role of microRNA variation and activity in PAH. We sought to examine the relationship among 16αOHE-mediated estrogen signaling, altered energy metabolism, and PAH by first conducting unbiased microRNA expression arrays from the lung tissue of PAH patients and Bmpr2 mutant mice. We discovered a shared upregulation in both species of the microRNA-29 (miR-29) family, which is known to regulate energy metabolism. 31, 32 We hypothesized that 16αOHE promotes HPAH via miR-29 family upregulation and that antagonism of miR-29 would attenuate PH in transgenic mouse models of Bmpr2 mutation.
Methods

Human Study Population
Vanderbilt Pulmonary Hypertension Research Cohort study participants were recruited via the Vanderbilt Pulmonary Hypertension Center, whereas Vanderbilt Pulmonary Fibrosis Research Cohort study participants were recruited via the Vanderbilt Pulmonary Fibrosis Program. The Vanderbilt University Medical Center Institutional Review Board approved all study protocols. All participants or their surrogate custodians as appropriate gave informed written consent to participate in genetic and clinical studies. Heritable PAH (HPAH) lung tissue samples (n=2) were obtained after informed consent was obtained at the time of postmortem autopsy. PAH was defined either by autopsy results showing plexogenic pulmonary arteriopathy in the absence of alternative causes such as congenital heart disease or by clinical and cardiac catheterization criteria as previously published. 33 HPAH was considered the type of PAH if a subject met 1 or both of the following criteria: family history of ≥2 subjects with confirmed PAH according to international standards of diagnostic criteria or detection of a mutation in a PAH-specific gene such as BMPR2. Idiopathic pulmonary fibrosis (IPF) lung tissue samples (n=2) were obtained after informed consent was obtained at the time of lung transplantation. IPF was defined according to the joint guidelines of the American Thoracic Society and European Respiratory Society. 34 Both subjects had echocardiograms suggestive of normal right ventricular pressure, morphology, and function. Control lung tissue was isolated from donor lungs purchased commercially (n=2; Lonza, Allendale, NJ). The human lung donor subjects from all 3 groups were female.
RNA Extraction and Preparation
Total RNA was isolated from 10-μm tissue sections with the use of the miRNeasy mini-kit (Qiagen, Valencia, CA) according to the manufacturer's guidelines. In brief, sample incubation was performed in Xylene at 50°C to remove excess paraffin. Samples were washed in ethanol. Proteins were degraded by digestion buffer with protease solution used as instructed. Isolation buffer and ethanol were used to bind samples to a spin-filter. DNAse treatment was used to degrade DNA. The filter was washed several times, and total RNA was eluted in 60 μL elution solution. A spectrophotometer was used to check total RNA quantity and quality (Nanodrop ND-1000, Thermo Scientific, Wilmington, DE). Before labeling and hybridization, samples were subject to RNA quality control to assess the integrity of the RNA, its content of small RNA, and its concentration with a Bioanalyzer (Agilent 2100 Bioanalyzer) and NanoDrop instruments.
MicroRNA Microarray Assays
Exiqon Services was used for microRNA array profiling. All experiments were conducted at Exiqon Services in Denmark. The quality of the total RNA was verified by an Agilent 2100 Bioanalyzer profile. Total RNA (250 ng) from sample and reference was labeled with Hy3 and Hy5 fluorescent label, respectively, with the miR-CURY LNA microRNA Hi-Power Labeling Kit, Hy3/Hy5 (Exiqon, Vedbaek, Denmark) following the procedure described by the manufacturer. The Hy3-labeled samples and a Hy5-labeled reference RNA sample were mixed pair-wise and hybridized to the miRCURY LNA microRNA array 6th generation (Exiqon), which contains capture probes targeting all microRNAs for humans, mice, or rats registered in the miRBASE 16.0. The hybridization was performed according to the miRCURY LNA microRNA array instruction manual with a Tecan HS4800 hybridization station (Tecan Austria). After hybridization, the microarray slides were scanned and stored in an ozone-free environment (ozone level <2.0 ppb) to prevent potential bleaching of the fluorescent dyes. The miRCURY LNA microRNA array slides were scanned with the Agilent G2565BA Microarray Scanner System (Agilent Technologies, Inc), and the image analysis was carried out with the ImaGene 9.0 software (BioDiscovery, Inc). The quantified signals were background corrected 35 (Normexp with offset value 10) and normalized with the use of the quantile normalization method, which we have found produces the best between-slide normalization to minimize the intensity-dependent differences between samples.
For murine tissue studies, the Exiqon miRCURY LNA microRNA array assays were performed after 4 weeks of gene activation in Rosa26-control and Rosa26-Bmpr2 delx4+ mice. The mice had received 4 weeks of either vehicle (polyethylene glycol) or 1.25 μg/h 16αOHE. Each array consisted of a pool of 3 mice, and 2 arrays were used per condition.
Log-transformed microRNA expression data have previously been shown to be normally distributed and thus were treated as such for current statistical analyses. 36 microRNA probes with expression levels at the level of background were eliminated from array results by guest on August 31, 2017 http://circ.ahajournals.org/
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Real-time reverse transcriptase (RT)-quantitative polymerase chain reaction (qPCR) was conducted on all samples to validate the microRNA profiling results. Specific miScript primer assays for miR-29a, miR-29b, and miR-29c (Qiagen, Valencia, CA) were used to verify the expression by qPCR. RT reactions were performed with miScript II RT kit (Qiagen). The reactions were in 20 μL total volume containing 100 ng total RNAs (including small RNAs), 1× miScript HiSpec buffer (1× miScript HiFlex buffer for RNU6B), 1× miScript Nucleics Mix, and 1× miScript Reverse Transcriptase Mix. The reactions were incubated for 1 hour at 37°C and then for 5 minutes at 95°C. All RT reactions were run in duplicate. Real-time PCR was performed on a StepOnePlus Real-Time PCR System (Applied Biosystems). The PCR included the RT product, miScript SYBR Green, and miScript primer assay (Qiagen). The reactions were incubated at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Relative expression was determined with the ΔΔCT method. RNU6B was used as the internal control according to manufacturer instructions and consistent with prior studies.
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Western Blot Analyses
Mouse or human lung tissue was homogenized in radioimmunoprecipitation assay buffer (PBS, 1% Ipegal, 0.5% sodium deoxycholate, 0.1% SDS) with proteinase and phosphatase inhibitor cocktails (Sigma-Aldrich, St. Louis, MO). Protein concentration was determined by BCA protein assay (Thermo Scientific, Rockford, IL). Primary antibodies used for Western blot included Glut4 (Abcam antibody), CD36 (Novus NB400-144), elastin (Abcam ab9514), peroxisome proliferator-activated receptor-γ (PPARγ; Abcam ab27649), and β-actin (Abcam ab8227).
Verification of miR-29 Direct Targets
The prediction of microRNA targets with bioinformatics algorithms has high false-positive and false-negative prediction rates. 38 Although false-positive prediction can be excluded by experiments, false-negative predictions would miss true targets. To further explore miR-29 potential direct targets, we used a direct affinity-purification method using a microRNA pull-down assay followed by specific quantitative PCR using established protocols. [39] [40] [41] In this approach, synthetic microRNA duplexes carrying a biotin group attached to the 3' end of the microRNA sense strand were transfected into murine pulmonary vascular smooth muscle cells. This resulted in the subsequent incorporation of the sense strand into the microRNA-induced silencing complex. After cell lysis, the microRNA-mRNA complexes were captured on streptavidin beads from which the mRNA was purified and analyzed with quantitative RT-PCR analysis of the affinity-purified mRNA. The PPARγ, CD36, and CAV1 genes were evaluated as genes of interest suspected to be directly bound by miR-29. Elastin and ABHD5, previously demonstrated targets of miR-29, were used as positive controls; in contrast, G6PC and HPRT were used as negative controls with regard to miR-29 direct targeting. 42, 43 More detailed information is provided in the online-only Data Supplement.
Animal Studies
Transgenic Mice
We used the previously described [44] [45] [46] Rosa26-rtTA2×TetO 7 , or Rosa26-Bmpr2 delx4+ mice had the transgene activated with doxycycline at 0.2 mg/g in chow. Mice were implanted with Alzet osmotic pumps delivering either vehicle alone (polyethylene glycol) or 16αOHE at 1.25 μg/h, a dose we previously demonstrated to promote a PAH phenotype in these mice. This dose was initially demonstrated to be a dose at which 16αOHE has significant estrogenic bioactivity in murine models. 22, 48 After 4 weeks with osmotic pumps, the mice underwent hemodynamic profiling and were euthanized and processed for microRNA purification.
We also performed experiments to antagonize miR-29 using an antagomir for miR-29 (α-miR29). LNA-anti-microRNAs were synthesized by Exiqon as an LNA-modified oligonucleotide that contained phosphorothioate backbone for use in microRNA functional studies. LNA-miR-29 was synthesized on the basis of the 5'-ATTTCAAATGGTGCT-3' sequence, which is complementary to miR-29. A scrambled oligonucleotide, LNA-Co, 5'-ACGTCTATACGCCCA-3', was chosen according to manufacturer instructions and used as control. The scrambled oligonucleotide was chosen because it met 3 requirements: (1) same nucleotide composition as the input sequence, (2) passed the same extensive siRNA filtering (eg, no low complex sequence), and (3) has the weakest (or no) match with any microRNA in the microRNA pool. LNA-antimicroRNAs were dissolved in saline and injected intravenously into mice via the tail vein once a week at a dose of 20 mg/kg. After 6 weeks, mice underwent hemodynamic phenotyping, as described below.
All animal procedures were approved by the Institutional Animal Care and Use Committee, Vanderbilt University School of Medicine (Nashville, TN).
Hemodynamic Phenotyping
Two-dimensional echocardiography was performed with a Vivo 770 High-Resolution Image System (VisuaSonics Toronto, ON, Canada). Echocardiograms, including B-mode, M-mode, and spectral Doppler images, were obtained the day before euthanasia with isoflurane anesthetic, as previously described. 21 Right ventricular systolic pressure (RVSP) was directly measured via insertion of a 1.4F Mikro-tip catheter transducer (Millar Instruments, Houston, TX) into a surgically exposed right internal jugular vein as previously described. 47 Pulmonary vascular resistance was calculated as (80×RVSP)/(3×cardiac output) as previously described.
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Immunostaining
Paraffin-embedded mouse lung sections were treated with a standard processing method for immunostaining and incubated with primary α-smooth muscle actin antibody (1:500; DAKO, Ft. Collins, CO) overnight, followed by Alexa 488 fluorescent secondary antibody (1:500, Invitrogen, Carlsbad, CA). All antibodies were diluted in a blocking buffer (Tris-buffered saline Tween with 10% FCS), and controls consisted of primary isotype with secondary antibody or secondary antibody only. Quantification of muscularization was performed by counting α-smooth muscle actin-positive vessels per field of view in paraffin-stained lung sections.
Immunolocalization of ceramides was performed on paraffinembedded mouse lung tissue. Lung sections were deparaffinized and rehydrated. The sections were blocked with 5% normal goat serum or 5% BSA, followed by an overnight incubation at 4°C with ceramide antibody (Enzo Life Sciences, Farmingdale, NY). The next day, the sections were incubated with biotinylated IgM secondary antibody followed by incubation with horseradish peroxidase-conjugated streptavidin. Diaminobenzidine was used as a substrate for horseradish peroxidase (Vector Labs, Burlingame, CA). The sections were dehydrated and mounted in Cytoseal 60 (Richard-Allan Scientific, Kalamazoo, MI) for light microscopic examination.
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Trichrome stain was performed on paraffin-embedded mouse lung sections. The trichrome stain reagents were purchased from Sigma-Aldrich, and the stain was performed according to manufacturer instructions.
Electron Microscopy
For electron microscopy studies, we used murine PASMCs and human endothelial-like cells derived from induced pluripotent stem cell lines as we previously described. 49 Cells were cultured in 100-mm dishes and were subjected for LNA-miR-Co or LNA-miR-29 transfections. Twenty-four hours after transfection, the cells were fixed in 2.5% gluteraldehyde in 0.1 mol/L cacodylate buffer at room temperature for 1 hour and then transferred to 4°C overnight.
Specimens were processed for transmission electron microscopy and imaged in the Vanderbilt Cell Imaging Shared Resource-Research Electron Microscope facility. Briefly, the samples were postfixed in 1% osmium tetraoxide at room temperature and then washed 3 times with 0.1 mol/L cacodylate buffer. Subsequently, the samples were dehydrated through a graded ethanol series, followed by incubation in 100% ethanol and propylene oxide and 2 exchanges of pure propylene oxide. Samples were embedded in epoxy resin and polymerized at 60°C for 48 hours. Ultrathin sections (70-80 nm) were then cut from the block and collected on 300-mesh copper grids. The copper grids were postsection stained at room temperature with 2% uranyl acetate and then with lead citrate. Samples were subsequently imaged on the Philips/FEI Tecnai T12 electron microscope at various magnifications.
Cells were randomly selected and pictured by a blinded observer in the electron microscopy core laboratory. All the mitochondria in the pictures were measured with tools from Image J, the open-source imaging program.
Insulin Resistance Measures
Insulin resistance was determined by the homeostasis model assessment of insulin resistance (HOMA-IR). This study was developed to model the dynamic interaction of insulin and glucose across a range of variations in insulin resistance and pancreatic β-cell function and correlates well with the degree of insulin sensitivity and resistance. [50] [51] [52] The HOMA-IR uses the following formula: fasting glucose (mmol/L)×fasting insulin (μU/mL)/22.5. Mouse plasma was used for studies involving the HOMA-IR assay. Studies were performed by the Hormone Assay and Analytic Services Core at Vanderbilt University.
Statistics
Statistical methods for array analysis are described above. For nonarray analyses with normal distribution, statistical significance was evaluated with the use of parametric statistical techniques with 2-sided testing, with a value of P<0.05 considered statistically significant. Statistical analysis was performed with the SPSS statistical package for Windows (version 21, IBM SPSS Statistics 21.0, Armonk, NY) or the JMP program (SAS Institute Inc, Cary, NC). Comparisons including multiple independent variables such as mutation status and 16αOHE or mutation status and presence of α-miR29 were performed with 2-way ANOVA, with the Fisher least significant difference as a post hoc test to determine the source of significance.
For principal components analysis, data were first normalized so that the average for each probe set was zero, and then the principal components analysis function in JMP was applied to all microRNA assessed by the Exiqon arrays. Eigenvectors for the first and second principal components were exported and plotted for Figures 1A and 2A. Given the nature of the study, there was no adjustment for multiple comparisons.
Results
Arrays Suggest Disease-Specific Changes in MicroRNA Expression in Human PAH
MicroRNA expression arrays were used to search for differences in expression that might contribute to PAH pathogenesis, recognizing that end-stage lung disease may influence microRNA expression independently of PAH. Thus, Exiqon microRNA arrays were used to determine expression levels in female lungs from HPAH and control and from female IPF subjects (Table) . Although IPF is also a global lung disease, the pathogenesis of IPF is distinct from that of PAH with the strict phenotypic selection we used. As a result, IPF subjects were included a priori as a mechanism to suggest whether any microRNA differences observed between HPAH and control lungs were a more generic result of global lung abnormality or a distinct feature of HPAH lungs not present in a separate lung disease (IPF).
The control subjects were healthy individuals who died in traumatic accidents. For each subject, 2 independent samples were taken, and for each disease state, a pooled set was run for comparison. Of 1439 microRNA probe sets, 196 were expressed above the noise in at least 1 IPF, PAH, or control subject. Principal components analysis showed that the 2 samples from each patient were nearly identical and that the 2 patients from each disease state clustered together closely ( Figure 1A ). Although the sample number is small, the low variability suggests a disease-specific effect. Comparing PAH and control shows that there were 65 probe sets with a 95% probability of at least a 30% change ( Figure 1B ). These included many probe sets described as regulating metabolism (marked by an asterisk), including the entirety of the miR29 cluster (miR-29a, miR-29b, and miR-29c). Upregulation of the miR-29 cluster was confirmed by quantitative RT-PCR with the use of RNA from control or PAH human lung ( Figure 1C ).
MiR-29 Is Induced by Both Bmpr2 Mutation and 16αOHE in Mice
We had previously published data suggesting that the primary pathogenic effect of estrogen in the context of BMPR2 mutation was related to deleterious effects on metabolism, including insulin resistance. 22 We thus wished to determine whether the estrogen metabolite 16αOHE contributed to the regulation of microRNAs known to relate to metabolism, with particular interest in the miR-29 family.
To determine whether we could use our Bmpr2 mutant murine model of PH to model the microRNA dysregulation found in human patients, Exiqon microRNA arrays were used to determine microRNA expression levels in male Rosa26-Bmpr2 delx4+ transgenic mice. Male mice were used because they allow a more direct control of estrogen exposure so that the predominant estrogen exposure in the model system is 16αOHE. A pool of microRNA from 3 mice was used for each microRNA expression array to compare mice that received vehicle (n=3) with those receiving the estrogen metabolite 16αOHE (n=3) in osmotic pumps as previously described. 22 Of 1209 probe sets, 303 had expression levels above background level. Principal components analysis on them clearly separates the groups (Figure 2A) , with the first principal component corresponding roughly to Bmpr2 mutation effect and the second principal component corresponding to 16αOHE effect, although the Bmpr2 mutant mice were already substantially moved on the 16αOHE effect axis. A heat map of the top 50 microRNAs with altered regulation showed the same microRNA cluster 29 in a group of genes with strong upregulation by 16αOHE in control mice and weaker upregulation in Bmpr2 mutant (microRNA labels with asterisks in Figure 2B ). This was confirmed by quantitative RT-PCR ( Figure 2C ), which found that the miR-29 cluster (miR-29a, miR-29b, and miR-29c) had a roughly 2-time-higher expression in activated Bmpr2 mutant mice lungs at baseline, increasing to 4-to 8-times upregulation with 16αOHE treatment.
Molecular Markers of Insulin Resistance Are Abnormal in Murine and Human PAH and Influenced by the Estrogen Metabolite 16αOHE and MiR-29
As mentioned, we recently reported a potential causal relationship between increased 16αOHE and increased PAH penetrance, including alterations in insulin resistance-related pathways. 22 Because we also recently found an association between glucocorticoid insensitivity and murine Bmpr2 PAH, 21 we explored molecular markers of insulin resistance using the same mice (vehicle [n=6] versus estrogen metabolite 16αOHE [n=6]) as in the microarray experiment described above and shown in Figure 2 (male Rosa26-Bmpr2 delx4+ transgenic mice; Figure 3 ).
Western blot analyses of whole mouse lung protein demonstrate that PPARγ and CD36 levels were each significantly reduced in wild-type animals exposed to 16αOHE compared with vehicle-treated wild-type animals. Bmpr2 mutant animals not exposed to 16αOHE had significantly reduced PPARγ and CD36 levels compared with vehicle-treated wildtype animals. Exposure of Bmpr2 mutant animals to 16αOHE further reduced both PPARγ and CD36 compared with Bmpr2 mutant animals treated with vehicle. These findings demonstrate that 16αOHE directly reduces PPARγ and CD36 levels and that the magnitude of reduction is higher in the setting of a Bmpr2 mutation ( Figure 3A) .
In addition, we analyzed the lung specimens from the human PAH subjects (n=2) evaluated by the whole lung microRNA array and the human control subjects (n=2) in the microarray study described in Figure 1 . Western blots show that PPARγ, GLUT4, and CD36 protein levels were substantially reduced in PAH patients (n=2, same as Figure 1 ) compared with control subjects (n=2, same as Figure 1 ; Figure 3B ).
Next, pulmonary microvascular endothelial cells cultured from the male Rosa26-Bmpr2 delx4+ transgenic mice were used to analyze in vitro protein production by endothelial cells. Cultured murine pulmonary microvascular endothelial cells from mice with the activated Bmpr2 mutation showed reduced levels of PPARγ, Glut4, and CD36 protein. These levels were further reduced by the addition of 16αOHE, consistent with the whole lung protein data ( Figure 3C ).
Because we suspect that metabolic irregularities are not cell specific, we believed that the mechanisms of interest would also be detectable in pulmonary vascular smooth muscle cells. We next hypothesized that antagonism of miR-29 would restore PPARγ and CD36 gene expression in vitro. Cultured mouse pulmonary vascular smooth muscle cells from male Rosa26-Bmpr2 delx4+ transgenic mice were used to assess the effect of α-miR29. We first assessed the specificity of miR-29 antagonism. Metrics used were known gene targets that the miR-29 family downregulates. Addition of α-miR29 improved the expression of known targets, that is, CD36, Col1a1, Eln, and peroxisome proliferatoractivated receptor gamma, coactivator 1α (Ppargc1a), but not related genes, suggesting specificity of miR-29 antagonism ( Figure 3D ). Although alteration of gene expression is important, microRNA modulation of gene and protein expression is often not equal, particularly given that many microRNAs influence the expression of genes into proteins at the posttranscriptional level. 53 The PPARγ and CD36 protein elevations on exposure to α-miR29 were confirmed by Western blot. Although CD36 protein was increased, PPARγ protein was significantly increased 14-fold in murine smooth muscle cell culture compared with control ( Figure 3E ).
MiR-29 Family Members MiR-29a and MiR-29c Directly Bind to the 3' Untranslated Region of the PPARγ gene
We next sought to determine whether miR-29 family members directly bind to the PPARγ gene, which would be a mechanism by which microRNAs influence gene expression. MicroRNA pull-down assays suggest that the 3' untranslated regions (UTRs) of the PPARγ and CAV1 genes, as well as the positive controls elastin and ABHD5, directly bind to miR29a and miR-29c (Figure 4) . miR-29b does not appear to bind to the 3' UTR of the negative control genes, as expected. In addition, the miR-29 family did not appear to bind to the 3' 
Antagonism of miR-29 Significantly Improves Hemodynamics and Other Features of PH in a Murine Model of PH
Transgene-activated Bmpr2 R899X mutant mice develop an anatomic, hemodynamic, and histological profile consistent with PH, and the penetrance is increased by 16αOHE. 22, 44, 45 We tested the hypothesis that miR-29 antagonism would prevent a pulmonary hypertensive phenotype in a study of animals of both sexes fed a Western diet. Bmpr2 R899X mutant mice of both sexes (n=25: female, n=12; male, n=13) had significantly elevated RVSP with the transgene activated compared with controls (n=13: female, n=6; male, n=7). Weekly injections of α-miR29 for 6 weeks significantly reduced RVSP ( Figure 5A ) among the Bmpr2 R899X mutation group (n=26: female, n=13; male, n=13) compared with controls (n=14: female, n=7; male, n=7), regardless of exposure to 16αOHE (squares) or vehicle (circles).
Other features of the hemodynamic profile were also improved by α-miR29 therapy. Pulmonary vascular resistance compared with controls (n=24: female, n=13; male, n=11) was elevated among Bmpr2 R899X mutant mice without (n=11: female, n=5; male, n=5) and with (n=11: female, n=7; male, n=4) 16αOHE, as previously demonstrated (no α-miR29 exposure). Twenty-three Bmpr2 R899X mice were exposed to α-miR29: 11 without 16αOHE (6 female, 5 male) and 12 with 16αOHE (6 female, 6 male). Pulmonary vascular resistance was significantly reduced among the Bmpr2 R899X mutant mice (n=23) treated with α-miR29 compared with those not treated with α-miR29 (n=22); this was true for Bmpr2 R899X mutant mice regardless of 16αOHE exposure ( Figure 5B ).
To assess histological changes associated with PH, the extent of pulmonary arterial muscularization was assessed. Control mice had significantly fewer muscularized small (<25-μm diameter) pulmonary arteries compared with Bmpr2 R899X mutant mice. α-miR29 treatment reversed increased the muscularization seen in Bmpr2 R899X mice but did not change muscularization in control mice (Figure 5C and 5D; each symbol is an animal and each column represents n=4 per group, with 2 females and 2 males per each group of 4). Because miR29 downregulation has been associated with renal fibrosis, careful examination of the kidneys from mice exposed to α-miR29 treatment was conducted by a renal pathologist. 54, 55 There was no evidence of fibrosis on careful review ( Figure II in the online-only Data Supplement).
Antagonism of miR-29 Reverses the Lung Molecular Phenotype Suggestive of Insulin Resistance
Whole lung from Bmpr2 R899X mutant mice have reduced PPARγ and CD36 protein levels compared with controls. Weekly α-miR29 treatment resulted in a significant increase in PPARγ and CD36 protein in both the control and Bmpr2 R899X mutant mice ( Figure 6A ). In addition, HOMA-IR is elevated among Bmpr2 R899X mutant mice. Control and Bmpr2 R899X mutant mice treated with α-miR29 have a significant reduction in HOMA-IR; among Bmpr2 R899X mutant mice, the level returns to that of controls ( Figure 6B ). We recently reported evidence for increased synthesis and deposition of ceramide associated with the PH phenotype in Bmpr2 R899X mutant mice and sought to assess ceramide in the lungs with and without α-miR29 treatment. 19 Ceramide is a key mediator of lipotoxicity elevated in the setting of insulin resistance. 56 As expected, ceramide appeared elevated in the pulmonary vasculature of Bmpr2 R899X mutant mice compared with controls, and α-miR29 treatment substantially reduced ceramide accumulation, consistent with an improvement in the molecular phenotype of insulin resistance ( Figure 6C ).
α-MiR29 Treatment Increases Average Mitochondrial Size
Our group and others have been interested in the contribution of mitochondrial abnormalities to PH, and we previously Figure 3 . Molecular markers of insulin resistance are regulated by disease, mutation, and estrogen. A, Peroxisome proliferatoractivated receptor-γ (PPARγ) and CD36 are suppressed by both Bmpr2 mutation and 16α-hydroxyestrone (16αOHE) treatment in whole mouse lung from male Rosa26-control (n=6) and Rosa26-Bmpr2 delx4+ mice (n=6). Each column corresponds to a mouse lung. Numbers are densitometry normalized to β-actin (β-Act). Group differences are significant by 2-way ANOVA for PPARγ (mutation effect, P<0.0001; estrogen effect, P=0.001; interaction, P=0.025) and CD36 (mutation effect, P=0.0003; estrogen effect, P<0.0001; interaction, P=0.002). B, PPARγ, GLUT4, and CD36 protein levels are strongly reduced in heritable pulmonary arterial hypertension (HPAH) patient (n=2) as compared with control (n=2) lung (each lane is a separate individual). C, In cultured murine pulmonary microvascular endothelial cells (PVMECs) from Rosa26-control (n=2) and Rosa26-Bmpr2 delx4+ mice (n=2), PPARγ, Glut4, and CD36 protein levels are reduced by Bmpr2 mutation and reduced further by addition of 16αOHE. D, Transfection of murine smooth muscle cells with a LNA-modified antisense miR-29 causes induction of the known targets CD36, Col1a1, Eln, and Ppargc1a (peroxisome proliferator-activated receptor gamma, coactivator 1α), but not related genes, showing specificity. *Targets that are significantly different from vehicle at P=0.025 by nonparametric median test. E, PPARγ protein is induced 14× and CD36 1.5× by anti-microRNA-29 in murine smooth muscle cell culture. showed that the global expression of a Bmpr2 mutation is sufficient to cause metabolic stress and mitochondrial oxidant injury, including excess production of mitochondrial-derived reactive oxygen species. 1, 20, 25, [57] [58] [59] This, in concert with the emerging appreciation that mitochondrial morphology is a dynamic process but that larger mitochondria may indicate reduced fission and associate with better outcomes in PAH, we sought to assess mitochondrial morphology with and without miR-29 antagonism. 25, 60 One mechanism by which miR-29 antagonism may correct energy metabolic problems is through the regulation of mitochondrial fission and fusion; the contributions of mitochondrial dynamics to pulmonary vascular disease and right ventricular response to stress are of great interest in the field. 61 The regulation of mitochondrial fission and fusion may occur via Ppargc1a or PPARγ increase, 62 as suggested by Figure 3D and 3E. We tested this by measuring the size of mitochondria in PASMCs derived from mice treated with the α-miR29 antagomir or vehicle ( The electron micrograph, which is a 2-dimensional section through a 3-dimensional object, probably understates the resolution of mitochondrial hyperfissioning. If the mitochondria are randomly oriented, we might expect for some to appear nearly circular (≈175 nmol/L in both dimensions) and some to have great length. Figure 7B and 7C provides visual examples of vehicle-or α-miR29-treated PASMCs, with mitochondrial long axes marked by arrows. Counts of mitochondria that appear more than twice as long as they are wide (long axis >400 nmol/L) are low in vehicle-treated PASMCs (8 of 160, 5%) compared with those treated with α-miR29 (56 of 177, 32%). This is a 6-fold increase We further assessed mitochondrial size using endotheliallike cells derived from human subjects. Specifically, we used induced pluripotent stem cells derived from a healthy control subject and from a patient with BMPR2 mutation-associated HPAH to derive endothelial-like cells for mitochondrial evaluation. Overall, mitochondria from healthy control endothelial-like cells were larger and more variable in size than mitochondria from HPAH patient endothelial-like cells. For both groups, treatment with α-miR29 increased mitochondrial size ( Figure 7E-7G ).
Discussion
In these experiments, we used human lung tissue and transgenic mouse models of mutant Bmpr2 to demonstrate that increased expression of miR-29 family is a shared feature of human and murine-modeled HPAH. We further demonstrate that functional and molecular markers of insulin resistance are abnormal in HPAH and that this effect is amplified by the estrogen metabolite 16αOHE and associated with elevated miR-29. Furthermore, in the setting of 16αOHE exposure, we demonstrate a beneficial effect of miR-29 antagonism in terms of disease penetrance, hemodynamics, and pulmonary histopathology in our murine model. While correcting the PH phenotype, treatment with α-miR29 also improved indexes of insulin resistance and metabolic dysregulation, as well as mitochondrial morphology. In summary, these findings support the concept that 16αOHE contributes to HPAH pathogenesis in the setting of a BMPR2 mutation and suggest that miR-29 antagonism may provide a novel therapeutic approach for HPAH.
Among the many perplexing features of human PAH, including HPAH, are the cell-level markers of altered energy metabolism, the systemic features of female predominance, and the association of PAH with insulin resistance and the metabolic syndrome. Independently of PAH, sex hormones are associated with insulin resistance and abnormalities of Figure 4 . Peroxisome proliferator-activated receptor-γ (PPARγ) and CAV1, but not CD36, are direct targets of microRNA-29a (miR-29a) and miR-29c. A, miRNA pull-down assays with subsequent quantitative reverse transcription-polymerase chain reaction (PCR) analysis of the affinity-purified mRNA demonstrate that both the PPARγ and CAV1 genes are bound at the 3' untranslated region by miR-29a and miR29c but not miR29b. Positive and negative controls were included in the assay. As expected, the elastin (ELN) and ABHD5 genes also are bound (positive controls), whereas G6PC and HPRT are not (negative controls). B, A 1.5% agarose gel loaded with 10 μL real-time PCR product demonstrating gene expression as a function of exposure to miR-29a, miR-29c, or scrambled miRNA duplex. miR-29 family direct targets show clear bands of correct size. Nontarget genes show no bands or smear.
by guest on August 31, 2017 http://circ.ahajournals.org/ Downloaded from energy metabolism, which may provide some clues as to how sex and metabolism interface. For example, in women, both subphysiological and supraphysiological estrogen levels associate with insulin resistance and type 2 diabetes mellitus, but in men, the association is strongest with high estrogen and low testosterone levels. [63] [64] [65] [66] However, these findings do not provide the precise mechanistic link between sex hormones, cellular and systemic metabolic abnormalities, and PAH.
MicroRNAs are short, single-stranded, non-protein-coding gene products typically 20 to 22 nucleotides long that posttranscriptionally regulate the expression of target genes through interactions with specific microRNAs. [67] [68] [69] There is certainly a growing recognition of the role that microRNAs play in cardiopulmonary diseases, including PAH. [70] [71] [72] [73] [74] [75] [76] [77] [78] Our finding on tissue microRNA arrays from HPAH patients and Bmpr2 transgenic mice showed a consistent pattern of microRNAs distinct from controls. The patterns were also consistent with previous studies related to insulin resistance and metabolic derangements, including a significant and consistent elevation of miR-29 family expression. 32, 79 Our subsequent studies demonstrated a molecular fingerprint consistent with insulin resistance and metabolic derangements that was attenuated by miR-29 antagonism in concert with hemodynamic improvement and improvement in the physiological HOMA-IR metric of insulin resistance. Although requiring replication, our results suggest that miR-29 contributes to HPAH pathogenesis, at least in the setting of elevated 16αOHE. We previously demonstrated that female and male HPAH patients have an estrogen milieu that R899X mutation, reducing the number of mice with RVSP outside the normal range from 17 of 25 to 6 of 26. Each symbol is the RVSP measured from 1 mouse; bars are averaged log-transformed values. By multiple-factor ANOVA, mutation effect was significant at P=0.0012, microRNA effect was significant at P=0.0004, and interaction between mutation and microRNA was significant at P=0.0146. All mice were fed a Western diet. Mice received 16α-hydroxyestrone (16αOHE; squares) or vehicle (circles) in pumps; the effect on RVSP was not significant (P=0.41; control, n=27; Bmpr2 R899X , n=51). Both male and female mice were used; this also had no effect on RVSP (P=0.40). B, Pulmonary vascular resistance. Each symbol is the value from 1 mouse. There was no difference between treatments in control mice; they are combined (n=24: 13 female, 11 male) for clarity. Bmpr2 R899X mice were given vehicle and no α-miR29 (n=11: 5 female, 6 male), 16αOHE without α-miR29 (n=11: 7 female, 4 male), vehicle and no α-miR29 (n=11: 6 female, 5 male), or 16αOHE+α-miR29 (n=12: 6 female, 6 male). By multiple-factor ANOVA, mutation effect was significant at P=0.0005, microRNA effect in the context of mutation was significant at P=0.003, and 16αOHE effect was significant at P=0.036. C, α-MiR29 treatment reversed increased muscularization seen in Bmpr2 R899X mice, as assessed by counting muscularized vessels in ten ×10 fields per animal, in 4 animals per group (each symbol is an animal; each column represents n=4 per group, with 2 female and 2 male per group). By multiple-factor ANOVA, mutation was significant at P=0.0148, microRNA effect was significant at P=0.0086, and differential microRNA effect in the context of mutation was significant at P=0.0252 (ie, α-miR29 reduces muscularization only in Bmpr2 R899X mice). D, Examples of fields from trichrome-stained lung sections from control and Bmpr2R899X mice with and without α-miR29 treatment (×200 magnification).
by guest on August 31, 2017 http://circ.ahajournals.org/ Downloaded from is skewed toward higher levels of 16αOHE, and we believe that this skewed sex hormone metabolism results in miR29 upregulation in HPAH. 12, 22 16αOHE binds to the estrogen receptors with high affinity, and we suspect that canonical signaling via estrogen receptor α or estrogen receptor β promotes enhances miR29 expression. 80 Importantly, our findings in the murine model did not differentiate according to sex, although mice of both sexes received exogenous 16αOHE in this study.
Our work has similarities and differences to recent work by Mair and colleagues Mair that demonstrated the beneficial effect of estrogen antagonism in attenuating PH in female murine models. Unlike the present study, that study found that although disease was attenuated in females, there was insufficient effect in the male subgroup. 8 This may be attributable to the naturally lower circulating levels of estrogens in males rather than an inherent inability of males to respond to estrogen antagonism. In our model, mice of both sexes were exogenously exposed to the estrogenic compound 16αOHE. Mair et al also found reduced lung aromatase levels in both cultured PASMCs and the pulmonary artery smooth muscle cell layer in the male compared with females animals. This finding suggests that an organspecific phenomenon related to local estrogen production and metabolism is also possible. Although we found no difference in murine PASMC mitochondrial size according to sex, association of mitochondrial fragmentation and dysmorphology with local aromatase activity is an area for future study.
We previously demonstrated that 16αOHE not only associates with human female HPAH in BMPR2 mutants but also amplifies HPAH penetrance and phenotype among Bmpr2 transgenic mice of both sexes. 22 Our present study is unique in that we identify a potential molecular mechanism for this effect: miR-29 promotion of metabolic derangements known to associate with HPAH and IPAH, including insulin resistance and alterations in lipid metabolism. 19, [26] [27] [28] [29] [30] Increased ceramide in the lungs suggests impairment of the fatty acid oxidation pathway. Consistent with this, we previously reported that endothelial cells with BMPR2 mutations have reduced expression of genes involved in fatty acid oxidation. 20 MiR-29 appears to be a critical node in the network of factors associated with glucose and lipid homeostasis, with regulatory roles linked to insulin secretion and the regulation of key lipid-metabolizing genes. 31, [81] [82] [83] Our data suggesting a link between the estrogen metabolite 16αOHE and miR-29 are novel in HPAH, although estradiol has previously been shown to induce miR-29 expression in a murine model of hepatic injury. 84 Our study had several limitations that warrant discussion. Although the subsequent findings presented suggest that elevated miR-29 is a feature of HPAH, the initial discovery of miR-29 elevation was made with a small number of specimens studied with an array platform that could result in false-positive results. In addition, the manner by which 16αOHE increases miR-29 is an opportunity for future study, although previous work suggests that the suppression of the nuclear factor-κB signaling pathway contributes. 84 Other mechanisms that promote derangements in energy metabolism, including how glucose flux and insulin resistance influence pulmonary vascular signaling in the human BMPR2 and mouse Bmpr2 mutant conditions, are not addressed by these studies and are areas for future study. Although our studies suggest a direct effect of miR-29 on PPARγ expression and energy metabolism, we recognize that alternative results from miR-29 activity that may be pathogenic are possible. In addition, it is notable that miR-29 antagonism improved CD36 and GLUT4 levels despite an absence of data to suggest direct binding of miR-29 to the 3' UTR of those genes. We suspect that this supports the growing body of literature suggestive that PPARγ directly regulates CD36 and GLUT4, but this requires further study. 85, 86 Furthermore, although reduced BMP signaling appears to be a central feature of many PAH forms, the work presented specifically concerns BMPR2-associated HPAH; whether these findings are directly applicable to other forms of PAH needs to be explored. Finally, we recognize that the complexity of sex hormone associations with regard to the heart adaptation to stress is not addressed by these studies; this may be particularly relevant given the growing concern that although women develop PAH more often, they also appear to live longer after diagnosis than men. 28, 87, 88 Finally, our findings require exploration in other animal models representative of PAH.
Conclusions
We demonstrate a potential mechanism by which 16αOHE promotes HPAH, with the finding of elevated miR-29 in human lung tissue from female patients with HPAH. We confirmed the presence of miR-29 family upregulation in a murine model of PAH using an exogenous estrogen metabolite (16αOHE) applied to animals with mutant Bmpr2 expression. Furthermore, the deleterious effects of 16αOHE, including the PAH phenotype, were attenuated by direct antagonism of miR-29. Coincident with phenotypic improvement, molecular and functional indexes of deranged energy metabolism were attenuated by miR-29 antagonism despite continued exposure to 16αOHE. Although further studies of the precise mechanism by which antagonism of miR-29 attenuates the HPAH phenotype and molecular alterations are warranted, novel therapeutic approaches to treat PAH without the complication of direct sex hormone modification may emerge.
CLINICAL PERSPECTIVE
Pulmonary arterial hypertension (PAH) is a highly fatal disease of the pulmonary vasculature with multiple risk factors, including the presence of mutations in the bone morphogenetic protein receptor type II gene, female sex, and abnormal sex hormone levels. Estrogens such as the metabolite 16α-hydroxyestrone (16αOHE) may contribute to PAH pathogenesis via several mechanisms, including alterations in cellular energy metabolism although the precise mechanisms remain unclear. In this study, we demonstrate that increased expression of the microRNA-29 (miR-29) family is a modifiable feature of bone morphogenetic protein receptor type II-associated heritable PAH (HPAH), which may have implications for pathogenesis and treatment, including a novel link with 16αOHE. First, we identified increased miR-29 in the lung tissue of human and murine-modeled HPAH. 16αOHE amplified murine-modeled HPAH in association with increased miR-29 levels and molecular markers of insulin resistance. Subsequently, in the setting of 16αOHE exposure, miR-29 antagonism reduced disease penetrance, hemodynamics, and pulmonary histopathology in murine-modeled HPAH. Furthermore, while correcting the pulmonary hypertension phenotype, treatment with miR-29 antagonism also improved indexes of insulin resistance and other markers of abnormal cellular energy metabolism. Together with the observation that female sex and female sex hormones associate with HPAH, our findings support the concept that 16αOHE contributes to HPAH pathogenesis in the setting of a bone morphogenetic protein receptor type II mutation, and this may occur via miR-29-promoting defects in cellular energy metabolism. Although further studies are needed, these findings may support novel therapeutic approaches to treat PAH without the complication of direct sex hormone modification. 
Verification of miR-29 direct targets
The prediction of miRNA targets using bioinformatics algorithms has high false positive and false negative prediction rates. 39 Though false positive prediction can be excluded by experiments, false negative predictions would miss true targets. To further explore miR-29 potential direct targets, we employed a direct affinity purification method using a miRNA pull-down assay followed by specific quantitative PCR using established protocols. [40] [41] [42] In this approach, synthetic miRNA duplexes carrying a biotin group attached to the 3' end of the miRNA sense strand were transfected into murine PVSMCs.
This resulted in the sense strand's subsequent incorporation into the miRNA-induced silencing complex (miRISC). After cell lysis, the miRNA-mRNA complexes were captured on streptavidin beads from which the mRNA was purified and analyzed using quantitative RT-PCR analysis of the affinity purified mRNA. The genes PPARγ, CD36, and CAV1 were evaluated as genes of interest suspected to be directly bound by miR-29. Elastin, and ABHD5 are known targets of miR-29 previously demonstrated, and used as positive controls; in contrast, G6PC and HPRT were used as negative controls with regard to miR-29 direct targeting. 43, 44 Affinity purification of miR-29 direct targets
The sense strand of miRNA was labeled with biotin at 3'UTR end. The sense and the guide strand was synthesized separately and was annealed to form miRNA duplex. The miRNA sense and guide strand were annealed in 10 mM Tris, pH 7.5, 20 mM NaCl.
The mixture was incubated for 2 minutes at 95° and then allowed to cool to room temperature on workbench for 2 hours. The miRNA duplex was transfected into murine miR29 probes produced a product at cycle numbers comparable to that in scrambled probe, and in which melt curves, above, were characteristic of non-specific products.
Specific products will have well-defined melt temperatures, as is the case for PPARγ in the figure above, which melts between 81 and 85 degrees C (black lines for triplicate products). By contrast, CD36 had no well defined melt temperature (grey lines), suggesting non-specific product or primer-dimers.
Supplemental Figure 2: Kidney histology
Mice exposed to α-miR29 treatment had no evidence of renal fibrosis upon histologic examination. In addition, there were no detectable abnormalities in terms of the renal glomeruli, tubules, or vasculature. Magnification, 20x. Supplemental Figure 3 
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